Infographic | MSLs by the numbers
Medical science liaisons are essential participants in most aspects of the commercialization process.
Data/Analytics
How data regulation could be good for marketing post-Cambridge Analytica
Stuart Ingis on the benefits of showing the public how advertisers and marketers use data and creating a global regulatory framework.
Former FDA commissioner Califf to pharma: opening up on health data requires overcoming risk
Califf spoke about the importance of more data to faster and cheaper drug development at the NewYorkBIO conference.
Trust in health sector takes a hit in major markets, Edelman research finds
The healthcare sector has suffered a dip in public trust in major markets including France, India and the US, but Britons remain among the more trusting globally, according to the Edelman Health Trust Barometer.
Infographic | A closer look at co-pay coupons and programs
Intriguing data on the economics and impact of co-pay coupons and programs
The Cambridge Analytica mess: What does it mean for pharma?
What happens in the world of Facebook cannot be ignored in pharma marketing. It increasingly lives in a world of data that is highly sensitive and must be managed well.
In [Insert Company Here] We Trust?
Whether it’s data or marketing dollars, there should be no surprises when you partner with a company.
Doctors who receive gifts from industry prescribe more branded drugs: study
In 2013, Medicare Part D prescribers who received a gift from a drugmaker prescribed 8% more brand-name drugs.
Study says drug development costs much less than previously estimated
New research suggests that the oft-cited $2.6 billion estimate for bringing a drug to market is significantly overstated.
Shutterstock says men are ‘more responsive’ to online ads
Images that “mirror the demographic profile of their target audience” perform best, according to an eye-tracking study from picture provider Shutterstock.
Want to read more?
Please login or register first to view this content.
